ReviewDiscover oncology2025
Global research dynamics in metabolic biomarkers and cancer: a bibliometric study from 2015 to 2025.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveMetabolic biomarkers are important for the early detection and prognostic assessment of cancer. Nevertheless, a bibliometric analysis examining their research landscape within this domain has not been performed. This study seeks to investigate the current research landscape of metabolic biomarkers related to cancer from 2015 to 2025 and to highlight emerging trends, offering valuable insights for future research directions.
methodsArticles published from 2015 to 2025 were extracted from the Web of Science database, and an analysis was performed utilizing R software, along with CiteSpace and VOSviewer.We retrieved clinical trials published between 2015 and 2025 from the PubMed database to analyze the clinical progress in this field.
resultsThis research encompassed 943 articles in total. Investigations into metabolic biomarkers related to cancer have demonstrated a consistent growth in publications between 2015 and 2023, which was succeeded by a significant surge from 2023 to 2024. The country with the highest number of publications is China, with the United States, the United Kingdom, Japan, and Italy following in that order. Furthermore, China has demonstrated exceptional performance in international collaboration, with the Chinese Academy of Sciences, Shanghai Jiao Tong University, and Zhejiang University emerging as the most prominent collaborative centers. Cancers is recognized as the journal that publishes the greatest quantity of articles within this domain, whereas PLOS One stands out as the journal with the highest citation frequency. Common keywords in the literature include terms such as 'risk,' 'metabolism,' and 'breast cancer.' Research hotspots primarily focus on their application across different cancer types, multi-omics and big data-driven discovery, and the development potential of microbiota-derived markers, and the lag of clinical transformation of metabolic biomarkers, etc.
conclusionThe vast promise that metabolic biomarkers hold for the diagnosis and treatment of cancer has attracted considerable interest from researchers across the globe. They are anticipated to emerge as a central theme in the future of cancer prevention and therapeutic strategies. This article offers an in-depth analysis of existing research, addresses key challenges in the field, and provides critical insights for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.